Timing of radiation and immunotherapy for lung cancer brain tumors
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial studies the best order and timing for combining radiation therapy and immunotherapy (a type of cancer drug) to treat lung cancer that has spread to the brain. Researchers want to see which approach works best and causes fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed lung cancer (non-small cell type) with tumors in the brain, shown on MRI scan
- Planning to receive radiation combined with an immunotherapy drug (PD-1/PD-L1 inhibitor)
- Overall health status allows for treatment; expected to live at least 3 months
- No previous brain radiation, brain surgery, or stereotactic radiation for brain tumors
- No active autoimmune disease requiring daily immune-suppressing medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted radiation treatment for brain tumors that have spread from lung cancer and may not have responded to other treatments. The goal is to see if this precise radiation approach can shrink these tumors and improve survival with fewer side effects.
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
This trial tests a combination of radiation to the brain plus chemotherapy and immunotherapy (anti-PD-1/PD-L1) for people with newly diagnosed non-small cell lung cancer that has spread to the brain. It is for those whose tumors do not have common driver mutations and whose brain metastases are causing symptoms.
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
Hear when a new Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.